For citations:
Volkova M.I., Abdelgafur A.M., Aivazov M.T., Amoev Z.V., Babina K.G., Borisov P.S., Vorontsovа A.A., Evstigneeva I.V., Evsyukova O.I., Zhelezin O.V., Kalpinsky A.S., Karabina E.V., Kirdakova N.V., Kolesnikov G.P., Kuzmina E.S., Latipova D.Kh., Leonenkov R.V., Maturov M.R., Meskikh A.V., Mishugin S.V., Ovchinnikova E.G., Olshanskaya A.S., Protsenko S.A., Semiglazova T.Yu., Smirnov R.V., Usynin E.A., Fael M.M., Cherniakova E.M., Shumskaya I.E. Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM. Cancer Urology. 2019;15(3):56-69. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-3-56-69
Email this article 